GlassScriptPhysician profile
Glenn S Schroyer
NPI 1336168780
$16,648.00
in general payments reported to CMS, 2019-2025
51 companies · $2,542 in 2025
The $2,542 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,531 · 2020: $1,709 · 2021: $2,587 · 2022: $2,795 · 2023: $2,853 · 2024: $2,631 · 2025: $2,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,026.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,387.73 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $2,151.64 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,877.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,407.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,230.70 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $1,140.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $609.17 | 2019-2024 | Spravato, Invega Sustenna |
| Pfizer INC. | $574.44 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $564.33 | 2019-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $406.56 | 2021-2025 | Rexulti, Abilify Maintena |
| Astellas Pharma US INC | $321.88 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $313.83 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Lundbeck LLC | $312.14 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $255.31 | 2019-2021 | |
| Allergan, INC. | $240.84 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Schroyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.